Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Nov 10, 2020LENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus SunitinibKENILWORTH, N.J., and WOODCLIFF LAKE, N.J., November 10, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new investigational data...
Nov 7, 2020Study 218 compares 18 mg and 14 mg starting doses of LENVIMA plus 5 mg everolimus in patients with clear-cell RCC following prior anti-angiogenic therapy, with prior anti-PD-1/PD-L1 therapy permittedEisai announced results from Study 218, a Phase 2 trial comparing the safety and efficacy of two different starting doses (18 mg versus 14 mg once daily) of LENVIMA, an orally available multiple...
- Nov 5, 2020Data includes an oral presentation on results from a Phase 2 trial evaluating starting doses of LENVIMA in combination with everolimus (LEN+EVE)
Eisai will present seven abstracts at the International Kidney Cancer Symposium (IKCS) 2020 from November 6-7, 2020. New investigational data from Study 218, a Phase 2 trial evaluating the safety...
-
Nov 2, 2020Nine presentations will highlight Eisai's investigational novel therapies being studied to treat Alzheimer's disease and its clinical symptoms
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of new data and research from the company's Alzheimer's disease (AD) pipeline, including...
- Oct 27, 2020AMGEN AND EISAI TO PARTICIPATE IN THE IMMUNE MODULATION DOMAIN OF REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS HOSPITALIZED WITH COVID-19
LOS ANGELES – (BUSINESS WIRE)--Global Coalition for Adaptive Research (LOS ANGELES, CA), Amgen (THOUSAND OAKS, CA), and Eisai Co., Ltd. (TOKYO, Japan “Eisai”) -- The Global Coalition for...